KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Gross Profit (2018 - 2025)

Historic Gross Profit for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $64.3 million.

  • Castle Biosciences' Gross Profit fell 831.37% to $64.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $274.6 million, marking a year-over-year increase of 751.7%. This contributed to the annual value of $271.9 million for FY2024, which is 5552.33% up from last year.
  • Per Castle Biosciences' latest filing, its Gross Profit stood at $64.3 million for Q3 2025, which was down 831.37% from $68.6 million recorded in Q2 2025.
  • Castle Biosciences' Gross Profit's 5-year high stood at $72.5 million during Q2 2024, with a 5-year trough of $19.0 million in Q3 2021.
  • Over the past 5 years, Castle Biosciences' median Gross Profit value was $39.1 million (recorded in 2023), while the average stood at $43.9 million.
  • In the last 5 years, Castle Biosciences' Gross Profit skyrocketed by 8633.15% in 2023 and then tumbled by 831.37% in 2025.
  • Castle Biosciences' Gross Profit (Quarter) stood at $20.4 million in 2021, then skyrocketed by 40.97% to $28.8 million in 2022, then surged by 86.33% to $53.7 million in 2023, then skyrocketed by 30.6% to $70.1 million in 2024, then dropped by 8.25% to $64.3 million in 2025.
  • Its last three reported values are $64.3 million in Q3 2025, $68.6 million for Q2 2025, and $71.6 million during Q1 2025.